Objectives: The aim of this paper is to discuss the mechanism underlying the pharmaceutical price gap and to estimate the relative profit margins of generic and brand-name drugs. Methods: Data were obtained from the drug list from the fifth to seventh waves of price adjustment and population claims data compiled by the National Health Insurance Database. Results: The analysis indicated that generic-to-brand price ratios and discount rates jointly determined generic-to-brand profit ratios. The profit margins of generic drugs were slightly higher than those of their brand-name counterparts. Competition between generic drugs reduced the generic-to-brand profit ratio, but therapeutic competition increased this ratio. Conclusions: The results of this study indicate that policy makers may select an appropriate generic-to-brand price ratio in order to improve resource allocation between generic and brand-name drug markets.
|Translated title of the contribution||Revisiting the pharmaceutical price gap|
|Original language||Chinese (Traditional)|
|Journal||Chinese Journal of Public Health|
|Publication status||Published - 2020 Feb 26|